Eli Lilly and Co.
(NYSE:LLY) on Thursday reported topline results from two pivotal Phase 3 trials for its investigational triple-hormone agonist, retatrutide.
The studies demonstrated significant weight reduction in adult patients managing obesity alongside severe complications, including type 2 diabetes and established cardiovascular disease.
In May, Eli Lilly said the TRIUMPH-1 trial of retatrutide showed patients losing as much as 28.3% of body weight after 80 weeks of treatment.
Read Also: Eli Lilly Highlights Weight Loss Benefits For Women Across Menopausal Stages Significant Weight Loss Across Trials The pharmaceutical developer, known for treatments like Zepbound and Foundayo, is testing retatrutide as a once-weekly medication that uniquely targets three distinct hormone receptors: GIP, GLP-1, and glucagon.
